Altogether, our results indicate that the elevated expression of BCL2L10 in melanoma contributes to cell survival upon treatment with different cytotoxic compounds, making BCL2L10 a promising target in the context of inhibiting anti-apoptotic Bcl-2 proteins in malignant melanoma treatment. Here, BCL2L10 is linked to melanoma.